A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects with Advanced Malignancies Previously Enrolled in Other XL184 Studies
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2014
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Exelixis
- 24 Sep 2014 Planned number of patients changed from 500 to 6, as reported by M.D. Anderson Cancer Center.
- 24 Sep 2014 Status changed from active, no longer recruiting to completed, as reported by M.D. Anderson Cancer Center.
- 01 Nov 2013 Planned number of patients changed from 6 to 500 as reported by M.D. Anderson Cancer Center.